American Century Companies Inc. Has $95.56 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

American Century Companies Inc. lowered its holdings in argenx SE (NASDAQ:ARGX) by 33.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 155,376 shares of the company’s stock after selling 76,533 shares during the quarter. American Century Companies Inc.’s holdings in argenx were worth $95,557,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ARGX. Steward Partners Investment Advisory LLC grew its stake in shares of argenx by 5.6% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock worth $234,000 after acquiring an additional 20 shares during the last quarter. SG Americas Securities LLC boosted its holdings in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after purchasing an additional 21 shares during the period. Farther Finance Advisors LLC grew its position in argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after purchasing an additional 21 shares during the last quarter. Dynasty Wealth Management LLC increased its holdings in shares of argenx by 3.4% during the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares during the period. Finally, Choreo LLC raised its position in shares of argenx by 4.4% during the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after buying an additional 23 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $607.95 on Tuesday. The business has a fifty day moving average of $633.44 and a 200-day moving average of $600.67. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21. The firm has a market cap of $36.94 billion, a PE ratio of -690.85 and a beta of 0.59.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. On average, analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ARGX shares. Wedbush restated an “outperform” rating and set a $655.00 price target on shares of argenx in a research note on Tuesday, December 3rd. Piper Sandler boosted their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. Sanford C. Bernstein raised shares of argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Finally, Citigroup reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, argenx currently has an average rating of “Moderate Buy” and an average target price of $687.00.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.